Showing results (61-70 of 81) with videos related to
Sort By:
Pageof 9
JAMA Oncology|November 23, 2022
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical TrialJoseph M Unger, Amy Darke, Megan Othus, et al.Journal of the American Academy of Dermatology|March 21, 2024
Germline cancer susceptibility in individuals with melanomaPauline Funchain, Ying Ni, Brandie Heald, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2020
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor ActivityShipra Gandhi, Manu R Pandey, Kristopher Attwood, et al.The Journal of Experimental Medicine|November 22, 2021
A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patientsChuan Li, Yee Peng Phoon, Keaton Karlinsey, et al.Journal for Immunotherapy of Cancer|June 26, 2020
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective studyYana G Najjar, Kristina Navrazhina, Fei Ding, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2020
Systemic Therapy for Melanoma: ASCO GuidelineRahul Seth, Hans Messersmith, Varinder Kaur, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2023
Systemic Therapy for Melanoma: ASCO Guideline UpdateRahul Seth, Sanjiv S Agarwala, Hans Messersmith, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateBryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineBianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.Pageof 9